{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T02:37:31Z","timestamp":1784601451586,"version":"3.55.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T00:00:00Z","timestamp":1712361600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T00:00:00Z","timestamp":1712361600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"crossref","award":["C14315\/A23464"],"award-info":[{"award-number":["C14315\/A23464"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"crossref","award":["C14315\/A23464"],"award-info":[{"award-number":["C14315\/A23464"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"crossref","award":["C14315\/A23464"],"award-info":[{"award-number":["C14315\/A23464"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"crossref","award":["C14315\/A23464"],"award-info":[{"award-number":["C14315\/A23464"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100023375","name":"Action Against Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023375","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Although changes in circulating tumour DNA (ctDNA) in breast cancer are well described, the kinetics of their fluctuations has not been described over short timescales. We investigated ctDNA dynamics during alternating cycles of chemotherapy and hormonal treatment in pre-treated patients with oestrogen receptor-positive metastatic breast cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients received alternating, 9-week cycles of eribulin and aromatase inhibitors (AIs). The clinical primary endpoint, progression-free survival (PFS), was monitored at 3, 6 and 9 months; secondary endpoints, clinical benefit rate (CBR), safety and tolerability profiles, were also assessed. Importantly, ctDNA fluctuations were monitored using the Oncomine\u2122 Breast cfDNA assay to test whether biomarkers may change rapidly between chemotherapy and aromatase inhibitor (AI) treatment in the setting of advanced breast cancer, potentially reflecting disease dynamics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The median PFS was 202 days (95% CI: 135-undefined) and 235 days (95% CI: 235-undefined) at 6 and 9 months, respectively, with a 50% CBR at both 6 and 9 months. Dynamic changes in ctDNA were observed in short timescales between chemotherapy and AI treatment and support the clinical benefit (CB) seen in individual patients and, critically, appear informative of acquired resistance in real time.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Changes in ctDNA can occur rapidly and reflect changes in patients\u2019 clinical tumour responses (NCT02681523).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10549-024-07316-8","type":"journal-article","created":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T01:01:24Z","timestamp":1712365284000},"page":"377-385","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Circulating tumour DNA dynamics during alternating chemotherapy and hormonal therapy in metastatic breast cancer: the ALERT study"],"prefix":"10.1007","volume":"206","author":[{"given":"Rebecca C.","family":"Allsopp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Page","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shradha","family":"Bhagani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Kasim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Badman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Kenny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1117-6947","authenticated-orcid":false,"given":"Justin","family":"Stebbing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline A.","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,6]]},"reference":[{"issue":"1","key":"7316_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A (2023) Cancer statistics, 2023, (in eng). CA Cancer J Clin 73(1):17\u201348. https:\/\/doi.org\/10.3322\/caac.21763","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"7316_CR2","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/s41416-021-01328-7","volume":"125","author":"F Luond","year":"2021","unstructured":"Luond F, Tiede S, Christofori G (2021) Breast cancer as an example of tumour heterogeneity and tumour cell plasticity during malignant progression. Br J Cancer 125(2):164\u2013175. https:\/\/doi.org\/10.1038\/s41416-021-01328-7","journal-title":"Br J Cancer"},{"issue":"4","key":"7316_CR3","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.ccell.2020.03.009","volume":"37","author":"AB Hanker","year":"2020","unstructured":"Hanker AB, Sudhan DR, Arteaga CL (2020) Overcoming endocrine resistance in breast cancer. Cancer Cell 37(4):496\u2013513. https:\/\/doi.org\/10.1016\/j.ccell.2020.03.009","journal-title":"Cancer Cell"},{"issue":"32","key":"7316_CR4","doi-asserted-by":"publisher","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","volume":"35","author":"MP Goetz","year":"2017","unstructured":"Goetz MP et al (2017) MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol 35(32):3638\u20133646. https:\/\/doi.org\/10.1200\/JCO.2017.75.6155","journal-title":"J Clin Oncol"},{"issue":"1","key":"7316_CR5","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s13058-018-1050-7","volume":"20","author":"GN Hortobagyi","year":"2018","unstructured":"Hortobagyi GN (2018) Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial. Breast Cancer Res 20(1):123. https:\/\/doi.org\/10.1186\/s13058-018-1050-7","journal-title":"Breast Cancer Res"},{"issue":"7","key":"7316_CR6","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1093\/annonc\/mdy155","volume":"29","author":"GN Hortobagyi","year":"2018","unstructured":"Hortobagyi GN et al (2018) Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol 29(7):1541\u20131547. https:\/\/doi.org\/10.1093\/annonc\/mdy155","journal-title":"Ann Oncol"},{"issue":"1","key":"7316_CR7","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1186\/s12885-018-4978-1","volume":"18","author":"A van Ommen-Nijhof","year":"2018","unstructured":"van Ommen-Nijhof A et al (2018) Selecting the optimal position of CDK4\/6 inhibitors in hormone receptor-positive advanced breast cancer \u2013 the SONIA study: study protocol for a randomized controlled trial. BMC Cancer 18(1):1146. https:\/\/doi.org\/10.1186\/s12885-018-4978-1","journal-title":"BMC Cancer"},{"key":"7316_CR8","unstructured":"Towle MJ, Nomoto K, Asano M, Kishi Y, Yu MJ, Littlefield BA (2012) Broad spectrum preclinical antitumor activity of eribulin (Halaven(R)): optimal effectiveness under intermittent dosing conditions. Anticancer Res 32(5):1611\u20131619. [Online]. Available: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22593439"},{"issue":"6","key":"7316_CR9","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1038\/bjc.2014.80","volume":"110","author":"T Yoshida","year":"2014","unstructured":"Yoshida T et al (2014) Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states. Br J Cancer 110(6):1497\u20131505. https:\/\/doi.org\/10.1038\/bjc.2014.80","journal-title":"Br J Cancer"},{"issue":"10","key":"7316_CR10","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1111\/cas.12488","volume":"105","author":"Y Funahashi","year":"2014","unstructured":"Funahashi Y et al (2014) Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models. Cancer Sci 105(10):1334\u20131342. https:\/\/doi.org\/10.1111\/cas.12488","journal-title":"Cancer Sci"},{"issue":"9769","key":"7316_CR11","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/S0140-6736(11)60070-6","volume":"377","author":"J Cortes","year":"2011","unstructured":"Cortes J et al (2011) Eribulin monotherapy versus treatment of physician\u2019s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 377(9769):914\u2013923. https:\/\/doi.org\/10.1016\/S0140-6736(11)60070-6","journal-title":"Lancet"},{"issue":"6","key":"7316_CR12","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1200\/JCO.2013.52.4892","volume":"33","author":"PA Kaufman","year":"2015","unstructured":"Kaufman PA et al (2015) Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 33(6):594\u2013601. https:\/\/doi.org\/10.1200\/JCO.2013.52.4892","journal-title":"J Clin Oncol"},{"key":"7316_CR13","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1200\/PO.20.00522","volume":"5","author":"K Page","year":"2021","unstructured":"Page K et al (2021) Circulating tumor DNA profiling from breast cancer screening through to metastatic disease. JCO Precis Oncol 5:1768. https:\/\/doi.org\/10.1200\/PO.20.00522","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"7316_CR14","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1158\/1078-0432.CCR-16-0825","volume":"23","author":"JA Shaw","year":"2017","unstructured":"Shaw JA et al (2017) Mutation analysis of cell-free DNA and single circulating tumor cells in metastatic breast cancer patients with high circulating tumor cell counts. Clin Cancer Res 23(1):88\u201396. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-0825","journal-title":"Clin Cancer Res"},{"issue":"2","key":"7316_CR15","doi-asserted-by":"publisher","first-page":"603","DOI":"10.21873\/anticanres.16196","volume":"43","author":"W Goto","year":"2023","unstructured":"Goto W et al (2023) Eribulin treatment promotes re-expression of estrogen receptor in endocrine therapy-resistant hormone receptor-positive breast cancer cells. Anticancer Res 43(2):603\u2013611. https:\/\/doi.org\/10.21873\/anticanres.16196","journal-title":"Anticancer Res"},{"issue":"1","key":"7316_CR16","doi-asserted-by":"publisher","first-page":"8","DOI":"10.4048\/jbc.2016.19.1.8","volume":"19","author":"J Ro","year":"2016","unstructured":"Ro J et al (2016) Patient management with eribulin in metastatic breast cancer: a clinical practice guide. J Breast Cancer 19(1):8\u201317. https:\/\/doi.org\/10.4048\/jbc.2016.19.1.8","journal-title":"J Breast Cancer"},{"issue":"1","key":"7316_CR17","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s13058-019-1235-8","volume":"21","author":"D Fernandez-Garcia","year":"2019","unstructured":"Fernandez-Garcia D et al (2019) Plasma cell-free DNA (cfDNA) as a predictive and prognostic marker in patients with metastatic breast cancer. Breast Cancer Res 21(1):149. https:\/\/doi.org\/10.1186\/s13058-019-1235-8","journal-title":"Breast Cancer Res"},{"issue":"5","key":"7316_CR18","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1093\/clinchem\/hvac220","volume":"69","author":"RC Allsopp","year":"2023","unstructured":"Allsopp RC et al (2023) A rapid, shallow whole genome sequencing workflow applicable to limiting amounts of cell-free DNA. Clin Chem 69(5):510\u2013518. https:\/\/doi.org\/10.1093\/clinchem\/hvac220","journal-title":"Clin Chem"},{"issue":"4","key":"7316_CR19","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1007\/s12282-017-0812-x","volume":"25","author":"K Araki","year":"2018","unstructured":"Araki K, Miyoshi Y (2018) Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K\/Akt\/mTOR in estrogen receptor-positive, HER2-negative breast cancer. Breast Cancer 25(4):392\u2013401. https:\/\/doi.org\/10.1007\/s12282-017-0812-x","journal-title":"Breast Cancer"},{"issue":"11","key":"7316_CR20","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/S1470-2045(22)00555-1","volume":"23","author":"FC Bidard","year":"2022","unstructured":"Bidard FC et al (2022) Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol 23(11):1367\u20131377. https:\/\/doi.org\/10.1016\/S1470-2045(22)00555-1","journal-title":"Lancet Oncol"},{"issue":"20","key":"7316_CR21","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","volume":"380","author":"F Andre","year":"2019","unstructured":"Andre F et al (2019) Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med 380(20):1929\u20131940. https:\/\/doi.org\/10.1056\/NEJMoa1813904","journal-title":"N Engl J Med"},{"key":"7316_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.810023","volume":"11","author":"SM Tolaney","year":"2021","unstructured":"Tolaney SM et al (2021) Abemaciclib in combination with endocrine therapy for patients with hormone receptor-positive, HER2-negative metastatic breast cancer: a phase 1b study. Front Oncol 11:810023. https:\/\/doi.org\/10.3389\/fonc.2021.810023","journal-title":"Front Oncol"},{"issue":"1","key":"7316_CR23","doi-asserted-by":"publisher","first-page":"210","DOI":"10.3390\/cancers14010210","volume":"14","author":"K Pandey","year":"2022","unstructured":"Pandey K et al (2022) Combination of abemaciclib following eribulin overcomes palbociclib-resistant breast cancer by inhibiting the G2\/M cell cycle phase. Cancers (Basel) 14(1):210. https:\/\/doi.org\/10.3390\/cancers14010210","journal-title":"Cancers (Basel)"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-024-07316-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-024-07316-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-024-07316-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T23:56:59Z","timestamp":1718668619000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-024-07316-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,6]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["7316"],"URL":"https:\/\/doi.org\/10.1007\/s10549-024-07316-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4004593\/v1","asserted-by":"object"}]},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,6]]},"assertion":[{"value":"1 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Justin Stebbing\u2019s conflicts can be found at\n                      \n                      ; none are relevant here. No other authors declare a conflict.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}